CN103735524A - Cefixime chewable tablet and preparation method thereof - Google Patents
Cefixime chewable tablet and preparation method thereof Download PDFInfo
- Publication number
- CN103735524A CN103735524A CN201310753967.2A CN201310753967A CN103735524A CN 103735524 A CN103735524 A CN 103735524A CN 201310753967 A CN201310753967 A CN 201310753967A CN 103735524 A CN103735524 A CN 103735524A
- Authority
- CN
- China
- Prior art keywords
- cefixime
- chewable tablet
- parts
- preparation
- mannitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a cefixime chewable tablet and a preparation method thereof. The method comprises the following steps: (1) screening cefixime through a 100-mesh screen, and respectively screening mannitol, a disintegrating agent, an adhesive, orange flavor and a lubricant for later use; (2) adding the cefixime, a sweetening agent, a disintegrating agent, an adhesive and a flavoring agent into a mixer, and uniformly mixing to obtain medicinal powder; and (3) adding magnesium stearate into the medicinal powder obtained in the step (2), uniformly mixing, and preparing the cefixime chewable tablet by adopting a method of directly tabletting powder. The cefixime chewable tablet disclosed by the method is good in taste and stable in quality, and the effective components of the medicine can be quickly absorbed through mouth mucosa by virtue of chewing. The cefixime chewable tablet is quick in absorption, high in bioavailability and remarkable in curative effect, and can solve the problems in the prior art.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, be specifically related to a kind of cefixime chewable tablet and preparation method thereof.
Background technology
Cefixime (Cefixime) is the third generation cephalo product that Japanese Fujisawa Pharmaceutical Co., Ltd develops, and within 1987, in Japan, goes on the market.Within 1998, in five developed countries in Europe, cefixime has exceeded cephalo monooctyl ester and cefaclor becomes the highest oral cephalosporin in market share.The whole world in 1999 is existing to be exceeded 80 countries and applies clinically cefixime.
China started import cefixime raw material and preparation in 1994.Cefixime raw material expires at the beginning of calendar year 2001 in the administrative protection of China application, and because its clinical effectiveness is obvious, determined curative effect and side effect are little, and therefore, its market demand is in recent years always in zooming passage.Clinical verification shows, cefixime has has a broad antifungal spectrum, sterilizing power is strong, lesion tissue drug level is high, to features such as beta-lactamase are extremely stable, safe, adverse reaction rate is low.Therapeutic effect for pharyngitis, tonsillitis, acute bronchitis, acute episode of chronic bronchitis, otitis media, urinary tract infection, cervicitis or urethritis etc. due to sensitive organism is remarkable.And, by clinical application monitoring situation, show, in recent years, always in rising trend as the clinical application amount of the cefixime of oral antibiotic.At present, cefixime has possessed ripe commercial processes route, still in the market introduction stage, and the profit that have than, secondary cephalo is higher.These factors, are comformed in bull spore series products cefixime and show one's talent.As the oral cephalo product of the third generation, cefixime is generally approved in clinical practice, also increase year after year of preparation demand, especially within 2007, selling, do well, within 2007, in the sales volume of sample hospital, 13,940 ten thousand yuan have been reached, future several years, the market share of cefixime is also by sustainable growth.
Chinese patent CN1803138A discloses a kind of cefixime oral disintegrating agent and preparation method thereof, and oral cavity disintegration tablet ubiquity physical strength is lower, the problem of easy friability, transportation and storage inconvenience.
Chinese patent CN103110607A discloses a kind of Cefixime Capsules and preparation method thereof, because Capsules has very few easily cracked, the too much easily characteristic of softening transform of water content.
Chinese patent CN101401810A discloses dispersible tablet of a kind of cefixime and preparation method thereof, and because of tablet extrusion forming, disintegrate is slower, and bioavailability is lower, and some patients were swallows more difficultly, thereby the use of tablet may be restricted to a certain extent.
Chewable tablet refers to be chewed or suckes the tablet of swallowing after clothes dissolve sheet in oral cavity, often adds sucrose, Herba Menthae wet goods sweeting agent and flavorant to adjust taste, and through chewing, rear surface is long-pending to increase tablet, can promote medicine dissolving and absorption in vivo.Taking convenience, can swallow, chew containing sucking or with taking after aqueous dispersion.Through chewing, rear surface is long-pending to increase tablet, even if can promote medicine dissolving and absorption in vivo also can guarantee to take medicine on time under exsiccosis, especially be applicable to old man, child, paralytic, the difficulty of swallowing and the poor patient of gastrointestinal function, can reduce medicine gastrointestinal is born.
Summary of the invention
The invention provides a kind of preparation method of cefixime chewable tablet, the steady quality of the cefixime chewable tablet that this preparation method makes, mouthfeel is good, absorbs fast and evident in efficacy.
A preparation method for cefixime chewable tablet, comprises the steps:
(1) cefixime is crossed to 100 mesh sieves, mannitol, disintegrating agent, binding agent, day orange essence and lubricant are crossed respectively 80 mesh sieves, standby;
(2) add mix homogeneously in mixer to obtain medicated powder cefixime, mannitol, disintegrating agent, binding agent and a day orange essence;
(3) magnesium stearate is added to mix homogeneously in the medicated powder that step (2) obtains, adopt direct powder compression to obtain described cefixime chewable tablet;
Wherein, the parts by weight of raw material used are as follows:
1500～2000 parts, 800～1200 portions of mannitol of cefixime
50～100 parts of 100～300 parts of binding agents of disintegrating agent
50～100 parts of 10～20 parts of lubricants of orange flavor.
In the present invention, cefixime is added to the adjuvant of suitable kind, using mannitol as sweeting agent, using orange flavor as correctives, and the cefixime chewable tablet preparing by direct powder compression, eliminated that cefixime has special micro-smelly, mouthfeel good, taking convenience, and the steady quality of the cefixime chewable tablet obtaining, medicine is by chewing, and its effective ingredient absorbs rapidly by oral mucosa, bioavailability is high, evident in efficacy.
Environmental condition may cause direct impact to tabletting, and when air humidity is too high, the more intense drug particles of hygroscopicity medicine occurs that the phenomenon of sticking is very obvious; When tabletting is excessive, the hardness of tablet is excessive, causes the prolonged disintegration of tablet, and too hour, tablet hardness is too small for pressure, and tablet is easy-formation not.As preferably, in step (3), during tabletting, ambient temperature is 20～30 ℃, and humidity is 50～70%;
The pressure of tabletting is 30～45KN, and tablet machine rotating speed is 10000～15000 slices/hour.Now, the good moldability of the tablet obtaining, unilateral bright and clean, there is not sticking phenomenon.
As preferably, described disintegrating agent is at least one in microcrystalline Cellulose, carboxymethyl starch sodium and polyvinylpolypyrrolidone.
As preferably, described binding agent is at least one in pregelatinized Starch, starch slurry and hydroxypropyl cellulose.
As preferably, described lubricant is at least one in magnesium stearate, micropowder silica gel and hydrogenated vegetable oil.
As further preferred, described cefixime chewable tablet, by the raw material of following weight portion, made:
1500～1800 parts, 1000～1200 portions of mannitol of cefixime
50～80 parts of 100～200 parts of pregelatinized Starch of microcrystalline Cellulose
50～80 parts of 10～20 parts of magnesium stearate of orange flavor.
While adopting these specific adjuvants, be convenient to obtain described cefixime chewable tablet by pressed powder, and the stability of the product obtaining is best, is more convenient for absorbing.
When described adjuvant is said components, as further preferred, in step (3), during tabletting, ambient temperature is 25～30 ℃, and humidity is 55～65%;
The pressure of tabletting is 35～45KN, and tablet machine rotating speed is 12000～13000 slices/hour, now, the tablet good moldability obtaining, unilateral bright and clean, do not occur sticking phenomenon, and the disintegrating property of tablet is good, be convenient to absorb.
The present invention also provides a kind of cefixime chewable tablet being prepared by said method, and this chewable tablet absorbs fast, bitterness without male offspring, taste good.
Compared with the existing technology, beneficial effect of the present invention is embodied in:
Described cephalo chewable tablet usage and dosage:
30 kilograms of above children of adult and body weight: oral, each 50-100mg(tires) (each 1/2-1), a twice-daily.In addition, can suitably increase and decrease according to age, body weight, symptom, to patient with severe symptoms, can each oral 200mg(tire) (each oral 2), a twice-daily.2, children's: oral, each 1.5-3mg(tires)/kg(body weight), a twice-daily.In addition, can also suitably increase and decrease according to symptom, for patient with severe symptoms, at every turn can oral 6mg(tire)/kg(body weight), a twice-daily
Tool of the present invention has the following advantages:
Adopt direct powder compression to granulate and to dry, can save the time of investment and the operation of granulation, drying plant, avoid the energy resource consumption of these two operations, aspect enhancing productivity, have great advantage.In adjuvant, selecting respectively mannitol and orange flavor is sweeting agent and correctives, the sense of discomfort of clean taste tart flavour without issue.Through chewing, rear surface is long-pending to increase tablet, can promote medicine dissolving and absorption in vivo, even if also can guarantee to take medicine on time under exsiccosis, be especially applicable to old man, child, paralytic, the difficulty of swallowing and the poor patient of gastrointestinal function, can reduce medicine gastrointestinal is born.Taking convenience, can swallow, chew containing sucking or with taking after aqueous dispersion.
The specific embodiment
Embodiment 1
Prescription: in 10000
Cefixime anhydride 1000g mannitol 1600g
Microcrystalline Cellulose 150g pregelatinized Starch 70g
Orange flavor 10g magnesium stearate 50g
Preparation method:
(1) cefixime is crossed 100 mesh sieves, and adjuvant is crossed respectively 80 mesh sieves, standby;
(2) by the cefixime anhydride of recipe quantity and mannitol, microcrystalline Cellulose, pregelatinized Starch, orange flavor to mix homogeneously in mixer;
(3) magnesium stearate is added in step (2) and mix 25 minutes, 25 ℃ of tabletting ambient temperatures are set, humidity 60% condition lower sheeting, tabletting pressure is controlled at 40KN, take rotating speed per hour as 12000, carries out tabletting, makes cefixime chewable tablet.
Embodiment 2
Prescription: in 10000
Cefixime anhydride 1100g mannitol 1500g
Microcrystalline Cellulose 120g pregelatinized Starch 60g
Orange flavor 15g magnesium stearate 60g
Preparation method:
(1) cefixime is crossed 100 mesh sieves, and adjuvant is crossed respectively 80 mesh sieves, standby;
(2) by the cefixime anhydride of recipe quantity and mannitol, microcrystalline Cellulose, pregelatinized Starch, orange flavor to mix homogeneously in mixer;
(3) magnesium stearate is added in step (2) and mix 25 minutes, 25 ℃ of tabletting ambient temperatures are set, the condition lower sheeting of humidity 55%, tabletting pressure is controlled at 35KN, take rotating speed per hour as 12500, carries out tabletting, makes cefixime chewable tablet.
Embodiment 3
Prescription: in 10000
Cefixime anhydride 1200g mannitol 1700g
Microcrystalline Cellulose 170g pregelatinized Starch 80g
Orange flavor 20g magnesium stearate 70g
Preparation method:
(1) cefixime is crossed 100 mesh sieves, and adjuvant is crossed respectively 80 mesh sieves, standby;
(2) by the cefixime anhydride of recipe quantity and mannitol, microcrystalline Cellulose, pregelatinized Starch, orange flavor to mix homogeneously in mixer;
(3) magnesium stearate is added in step (2) and mix 30 minutes, 30 ℃ of tabletting ambient temperatures are set, the condition lower sheeting of humidity 65%, tabletting pressure is controlled at 45KN, take rotating speed per hour as 13000, carries out tabletting, makes cefixime chewable tablet.
Embodiment 4
Prescription: in 10000
Cefixime anhydride 1200g aspartame 1500g
Low-substituted hydroxypropyl cellulose 150g pregelatinized Starch 80g
Chocolate essence 15g magnesium stearate 70g
(1) cefixime is crossed 100 mesh sieves, and adjuvant is crossed respectively 80 mesh sieves, standby;
(2) by the cefixime anhydride of recipe quantity and aspartame, low-substituted hydroxypropyl cellulose, pregelatinized Starch, chocolate essence to mix homogeneously in mixer;
(3) magnesium stearate is added in step (2) and mix 25 minutes, 25 ℃ of tabletting ambient temperatures are set, humidity 60% condition lower sheeting, tabletting pressure is controlled at 40KN, take rotating speed per hour as 12000, carries out tabletting, makes cefixime chewable tablet.
The long-term stable experiment that embodiment 1～4 is carried out 12 months is investigated check (2010 editions two appendix of Chinese Pharmacopoeia), and result is as follows:
As seen from the above table, the present invention, by the control of adjuvant special ratios and preparation parameter, show that a kind of mouthfeel is better, steady quality, and disintegrate is cefixime chewable tablet faster.
By some experimental datas, therapeutic effect of the present invention is described below:
Following data are entrusted the clinical trial of the cefixime chewable tablet of Shenyang Yiling Pharmaceutical Technology Co., Ltd.'s organizing and implementing by our company, adopt cefixime treatment children's bacterial diarrhoea to obtain promising result, now relevant data are summarized and are analyzed as follows:
1, clinical data
Observe altogether treatment 100 examples, be divided at random each 50 examples for the treatment of group and matched group.In treatment group, male 29 examples, female's 21 examples, 1～12 years old age, average (6.8 ± 1.2) year, the course of disease 1 day～12 days, average (3.5 ± 1.5) day, wherein, bacillary dysentery 21 examples, escherichia coli enteritis 23 examples, other 6 examples.In matched group, male 27 examples, female's 23 examples, 1～11 years old age, average (6.5 ± 1.5) year, the course of disease 2 days～12 days, average (3.5 ± 1.2) day, wherein, bacillary dysentery 20 examples, escherichia coli enteritis 24 examples, other 6 examples.The serious underlying diseases in aspect such as selected all infants have all been got rid of intentionally, liver, kidney.The physical data comparison of two groups of infants, the equal not statistically significant of difference (P ﹥ 0.05), has clinical comparability.
2, Therapeutic Method
Treatment group: the cefixime chewable tablet (100mg*12 sheet) making according to the same method of embodiment 1 is oral, each 1.5-3mg(tires)/kg(body weight), a twice-daily.In addition, can also suitably increase and decrease according to symptom, for patient with severe symptoms, at every turn can oral 6mg(tire)/kg(body weight), a twice-daily.
Contrast groups: Shenzhen City Pharmaceutical Factory, oral, by 1.5～3.0mg/kg of body weight, 2 times on the one, in addition, according to symptom, suitably increase and decrease, for severe cases, by 6mg/kg of body weight, 2 times on the one.
All be decided to be 5～14 days according to the state of an illness course for the treatment of of two groups of infants.
3, therapeutic outcome
Finish rear evaluation infant curative effect the course for the treatment of, cure: transference cure, stool for routine normally and is just cultivated negative; Take a turn for the better: just time minimizing and chemical examination take a turn for the better; Invalid: symptom does not disappear, stool examination is still abnormal.
(1) Clinical efficacy comparison, in Table 2
Table 2 liang group curative effect comparison
| Group | Number of cases | Effective | Effectively | Invalid |
| Treatment group | 50 | 34（68.0%） | 15（30.0%） | 1（2.0%） |
| Matched group | 50 | 26（52.0%） | 21（42.0%） | 3（6.0%） |
(2) stool situation comparison, in Table 3.
Table 3 liang group symptom comparison
Described in comprehensive, not only steady quality of cefixime chewable tablet of the present invention, medicine is by chewing, its effective ingredient absorbs rapidly by oral mucosa, absorbs soon, and bioavailability is high, effect in children's bacterial diarrhea treatment is good, and without obvious adverse reaction.
Claims (8)
1. a preparation method for cefixime chewable tablet, is characterized in that, comprises the steps:
(1) cefixime is crossed to 100 mesh sieves, mannitol, disintegrating agent, binding agent, orange flavor and lubricant are crossed respectively 80 mesh sieves, standby;
(2) add mix homogeneously in mixer to obtain medicated powder cefixime, mannitol, disintegrating agent, binding agent and orange flavor;
(3) magnesium stearate is added to mix homogeneously in the medicated powder that step (2) obtains, adopt direct powder compression to obtain described cefixime chewable tablet;
Wherein, the parts by weight of raw material used are as follows:
1500～2000 parts, 800～1200 portions of mannitol of cefixime
50～100 parts of 100～300 parts of binding agents of disintegrating agent
50～100 parts of 10～20 parts of lubricants of orange flavor.
2. the preparation method of cefixime chewable tablet according to claim 1, is characterized in that, in step (3), during tabletting, ambient temperature is 20～30 ℃, and humidity is 50～70%;
The pressure of tabletting is 30～45KN, and tablet machine rotating speed is 10000～15000 slices/hour.
3. the preparation method of cefixime chewable tablet according to claim 1 and 2, is characterized in that, described disintegrating agent is at least one in microcrystalline Cellulose, carboxymethyl starch sodium and polyvinylpolypyrrolidone.
4. the preparation method of cefixime chewable tablet according to claim 1 and 2, is characterized in that, described binding agent is at least one in pregelatinized Starch, starch slurry and hydroxypropyl cellulose.
5. the preparation method of cefixime chewable tablet according to claim 1 and 2, is characterized in that, described lubricant is at least one in magnesium stearate, micropowder silica gel and hydrogenated vegetable oil.
6. the preparation method of cefixime chewable tablet according to claim 1, is characterized in that, by the raw material of following weight portion, is made:
1500～1800 parts, 1000～1200 portions of mannitol of cefixime
50～80 parts of 100～200 parts of pregelatinized Starch of microcrystalline Cellulose
50～80 parts of 10～20 parts of magnesium stearate of orange flavor.
7. the preparation method of cefixime chewable tablet according to claim 6, is characterized in that, in step (3), during tabletting, ambient temperature is 25～30 ℃, and humidity is 55～65%;
The pressure of tabletting is 35～45KN, and tablet machine rotating speed is 12000～13000 slices/hour.
8. a cefixime chewable tablet, is characterized in that, by the preparation method of claim 1～7 any one, is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310753967.2A CN103735524B (en) | 2013-12-30 | 2013-12-30 | A kind of Cefixime chewable tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310753967.2A CN103735524B (en) | 2013-12-30 | 2013-12-30 | A kind of Cefixime chewable tablet and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103735524A true CN103735524A (en) | 2014-04-23 |
| CN103735524B CN103735524B (en) | 2015-10-21 |
Family
ID=50492642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310753967.2A Active CN103735524B (en) | 2013-12-30 | 2013-12-30 | A kind of Cefixime chewable tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103735524B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104490808A (en) * | 2014-12-05 | 2015-04-08 | 海南卫康制药(潜山)有限公司 | Cefixime composition chewable tablets and preparation method thereof |
| CN106420642A (en) * | 2016-10-14 | 2017-02-22 | 全椒先奇医药科技有限公司 | Cefixime chewable tablet and preparation method thereof |
| CN113440530A (en) * | 2021-07-08 | 2021-09-28 | 广州白云山医药集团股份有限公司白云山制药总厂 | Cefixime medicament and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007536378A (en) * | 2004-05-10 | 2007-12-13 | ルピン・リミテッド | New cefixime pharmaceutical formulation with enhanced bioavailability |
| CN101606913A (en) * | 2009-07-16 | 2009-12-23 | 广州白云山制药股份有限公司广州白云山制药总厂 | Cefixime dispersible tablet and preparation method thereof |
-
2013
- 2013-12-30 CN CN201310753967.2A patent/CN103735524B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007536378A (en) * | 2004-05-10 | 2007-12-13 | ルピン・リミテッド | New cefixime pharmaceutical formulation with enhanced bioavailability |
| CN101606913A (en) * | 2009-07-16 | 2009-12-23 | 广州白云山制药股份有限公司广州白云山制药总厂 | Cefixime dispersible tablet and preparation method thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104490808A (en) * | 2014-12-05 | 2015-04-08 | 海南卫康制药(潜山)有限公司 | Cefixime composition chewable tablets and preparation method thereof |
| CN106420642A (en) * | 2016-10-14 | 2017-02-22 | 全椒先奇医药科技有限公司 | Cefixime chewable tablet and preparation method thereof |
| CN113440530A (en) * | 2021-07-08 | 2021-09-28 | 广州白云山医药集团股份有限公司白云山制药总厂 | Cefixime medicament and preparation method thereof |
| CN113440530B (en) * | 2021-07-08 | 2023-08-08 | 广州白云山医药集团股份有限公司白云山制药总厂 | Cefixime medicine and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103735524B (en) | 2015-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1523974B1 (en) | Composition for rapid disintegrating tablet in oral cavity | |
| CN101352449B (en) | Vitamin orally disintegrating tablet and preparation method thereof | |
| JP5332615B2 (en) | Orally disintegrating tablet and method for producing the same | |
| US20050155519A1 (en) | Granulation process | |
| CN101283991B (en) | Orally-disintegrating tablet and manufacturing method thereof | |
| CN106420643B (en) | A kind of chewable tablets and preparation method thereof containing vitamine C sodium | |
| CN104244930A (en) | Orally disintegrating tablet and method for producing same | |
| JP5342028B2 (en) | Orally disintegrating tablets | |
| CN102038645A (en) | Desloratadine grain and preparation method thereof | |
| CN101461788B (en) | Phloroglucine orally disintegrating tablet and preparation method thereof | |
| CN101143135B (en) | Melatonin orally disintegrating tablet and preparation method thereof | |
| CN100546571C (en) | Sangju effervescent tablet for treating common cold | |
| CN101209249A (en) | Spaston orally disintegrating tablets and preparation thereof | |
| CN103735524B (en) | A kind of Cefixime chewable tablet and preparation method thereof | |
| CN103826660B (en) | Orally disintegrating tablet containing hydroxy alkyl cellulose particulate | |
| CN110612123A (en) | Composition for disintegrating tablet containing microfibrillar cellulose and active ingredient | |
| CN106265941A (en) | A kind of Chinese medicine composition for treating oral ulcer and its oral cavity disintegration tablet and application thereof | |
| CN101904827A (en) | Orally disintegrating tablet of ambroxol hydrochloride and preparation method thereof | |
| CN108261399A (en) | Olanzapine oral disnitegration tablet and preparation method thereof | |
| CN100542520C (en) | Lonicera and Forsythia effervescent | |
| CN104435216A (en) | Ephedra and apricot cough relieving traditional Chinese medicine dispersible tablet and preparation method thereof | |
| CN103393612A (en) | Preparation method for enalapril maleate orally disintegrating tablets | |
| CN101912613A (en) | Taste masking preparation | |
| CN100506237C (en) | Seabuckthorn preparation and its preparing process | |
| CN100482226C (en) | Composition for covering flavor and preparation of containing the composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: Haikou national high tech Zone Industrial Park two trough trough four road 570311 Hainan city of Haikou province No. 8 Patentee after: HAINAN HULUWA PHARMACEUTICAL GROUP CO., LTD. Address before: Haikou national high tech Zone Industrial Park two trough trough four road 570311 Hainan city of Haikou province No. 8 Patentee before: Hainan Gourd Doll Pharmaceutical Co., Ltd. |